Key facts
- This page summarizes Mariana Nacht's Form 4 filing for LogicBio Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Nov 2022, 20:12.
Mariana Nacht - 16 Nov 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 16 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Nov 2022, 20:12:12 UTC
- Prior SEC filing
- 03 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frederic Chereau, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mariana Nacht filed Form 4 for LogicBio Therapeutics, Inc. on 17 Nov 2022.
Change
- Previous filing in this sequence was filed on 03 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LOGC
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.7000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Mariana Nacht is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the LogicBio Therapeutics, Inc. (the "Company") on each vesting date.
Footnote F2
Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.